Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
30
SPRY Quote, Financials, Valuation and Earnings
Last price:
$11.14
Seasonality move
:
3.32%
Day range:
$10.95 - $11.82
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
7.55x
P/B ratio:
7.34x
Volume:
1.7M
Avg. volume:
1.8M
1-year change:
-1.97%
Market cap:
$1.1B
Revenue:
$89.1M
EPS (TTM):
-$0.81
Analysts' Opinion
-
Consensus RatingARS Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.83, ARS Pharmaceuticals, Inc. has an estimated upside of 162.84% from its current price of $10.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $10.97.
Fair Value
-
According to the consensus of 6 analysts, ARS Pharmaceuticals, Inc. has 162.84% upside to fair value with a price target of $28.83 per share.
SPRY vs. S&P 500
-
Over the past 5 trading days, ARS Pharmaceuticals, Inc. has underperformed the S&P 500 by -4.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ARS Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ARS Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter ARS Pharmaceuticals, Inc. reported revenues of $32.5M.
Earnings Growth
-
ARS Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter ARS Pharmaceuticals, Inc. reported earnings per share of -$0.52.
Enterprise value:
893.9M
EV / Invested capital:
--
Price / LTM sales:
7.55x
EV / EBIT:
--
EV / Revenue:
6.26x
PEG ratio (5yr expected):
-0.23x
EV / Free cash flow:
-10.39x
Price / Operating cash flow:
96.16x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$127.2M
Return On Assets:
-25.29%
Net Income Margin (TTM):
-56.06%
Return On Equity:
-38.98%
Return On Invested Capital:
-35.53%
Operating Margin:
-163.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3M | $2.6M | $142.8M | $2.1M | $32.5M | |
| Gross Profit | -$31K | $2.4M | $127.2M | $1.9M | $24.3M | |
| Operating Income | -$71.4M | -$60.5M | -$90.8M | -$21.7M | -$53.2M | |
| EBITDA | -$72.3M | -$60.4M | -$89.7M | -$21.7M | -$52.8M | |
| Diluted EPS | -$0.21 | -$0.51 | -$0.81 | -$0.20 | -$0.52 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $305.4M | $270.8M | $244.5M | $208.5M | $338.9M | |
| Total Assets | $352.6M | $271.1M | $248.6M | $217.6M | $372.8M | |
| Current Liabilities | $15.3M | $4M | $11.2M | $16.6M | $50.9M | |
| Total Liabilities | $20.4M | $4M | $11.3M | $16.6M | $225.1M | |
| Total Equity | $332.1M | $267.1M | $237.3M | $201M | $147.7M | |
| Total Debt | $5.1M | -- | $92K | -- | $97.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.5M | -$45.9M | -$85.4M | -$14.5M | -$47M | |
| Cash From Investing | -$112.7M | $21.7M | -$69.1M | $16.8M | -$45M | |
| Cash From Financing | $194.5M | $3.3M | $174.4M | $680K | $100M | |
| Free Cash Flow | -$30.2M | -$46M | -$86M | -$14.6M | -$47.2M | |
SPRY
Sector
Market Cap
$1.1B
$28.1M
Price % of 52-Week High
58.04%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-2.51%
-1.55%
1-Year Price Total Return
-1.97%
-19.36%
Beta (5-Year)
0.796
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.42
200-day SMA
Sell
Level
$12.80
Bollinger Bands (100)
Buy
Level
8.63 - 12.11
Chaikin Money Flow
Sell
Level
-15.5M
20-day SMA
Buy
Level
$10.81
Relative Strength Index (RSI14)
Buy
Level
54.65
ADX Line
Buy
Level
32.73
Williams %R
Neutral
Level
-46.1538
50-day SMA
Buy
Level
$9.54
MACD (12, 26)
Buy
Level
0.55
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
87.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.3671)
Buy
CA Score
(Annual)
Level (1.1418)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-5.8563)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, SPRY has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SPRY average analyst price target in the past 3 months is $28.83.
-
Where Will ARS Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ARS Pharmaceuticals, Inc. share price will rise to $28.83 per share over the next 12 months.
-
What Do Analysts Say About ARS Pharmaceuticals, Inc.?
Analysts are divided on their view about ARS Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ARS Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is ARS Pharmaceuticals, Inc.'s Price Target?
The price target for ARS Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $28.83 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SPRY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ARS Pharmaceuticals, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SPRY?
You can purchase shares of ARS Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ARS Pharmaceuticals, Inc. shares.
-
What Is The ARS Pharmaceuticals, Inc. Share Price Today?
ARS Pharmaceuticals, Inc. was last trading at $11.14 per share. This represents the most recent stock quote for ARS Pharmaceuticals, Inc.. Yesterday, ARS Pharmaceuticals, Inc. closed at $10.97 per share.
-
How To Buy ARS Pharmaceuticals, Inc. Stock Online?
In order to purchase ARS Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SPRY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SPRY
Sector
P/E ratio
174.21x
24.09x
PEG ratio
-0.23x
-0.01x
P/B ratio
7.34x
1.83x
Price / LTM sales
7.55x
1.59x
Growth Metrics
SPRY
Sector
Revenue growth
1471.62%
4.68%
Earnings growth
-162.66%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.47
-$0.18
Profitability
SPRY
Sector
Profitability FY 2024
$88M
$3.6M
Return on invested capital
-35.53%
-31.87%
Return on assets
-25.29%
-28.18%
Return on equity
-38.98%
-37.89%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
9
Balance Sheet
SPRY
Sector
Total cash
$288.2M
$26.2M
Short term investments
$263.2M
$25.7M
Total assets
$351.2M
$76.7M
Long term debt
$97.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
